ASCO GU 2018: Real-world Survival and Treatment Patterns of Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with Second-line Therapy After Platinum-based Chemotherapy

San Francisco, CA (UroToday.com) The median overall survival for patients with locally advanced/metastatic urothelial carcinoma (UC) who fail standard platinum-containing chemotherapy is 5–7 months, and there is no current standard of care for these patients. As immuno-oncology (IO) therapies are being developed for the treatment of UC, a better understanding of the current real-world treatment patterns and effectiveness of treatments is needed.

The authors analyzed patients with locally advanced/metastatic UC receiving second-line therapy after platinum-based chemotherapy were identified from the Flatiron Oncology electronic medical record database from 2011–2016. Treatment patterns, including the most common regimens and total number of systemic therapy treatment lines, were characterized.

A total of 476 patients were included with a mean age of 70.1 ± 9.2 years and 74.2% were male. Less than 3% were tested for PD-L1 during follow-up. Platinum-based chemotherapies were most commonly prescribed (Table 1), 4.4% received IO during second-line. Median OS from start of second-line therapy was 8.3 months (95% CI: 7.2–8.9).

Real-world overall survival (OS) among locally advanced/metastatic UC patients who received second-line therapy after platinum-based chemotherapy was less than one year, similar to prior estimates. It remains to be seen how the introduction and increasing usage of IO may affect OS.

Screen Shot 2018 02 10 at 6.43.53 PM
Speaker: Jason C. Simeone, Evidera

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, Twitter:@GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA